Targeted therapy for neuroblastoma: ALK inhibitors

Klinische Padiatrie

Volumn 225, Issue 6, 2013, Pages 303-308

  Schulte, Johannes Hubertus ^a,b,c   Schulte, S ^b   Heukamp, L C ^d   Astrahantseff, K ^e   Stephan, H ^b   Fischer, M ^f   Schramm, A ^b   Eggert, A ^e  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

crizotinib; LDK 378; LDK378; pediatric cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANAPLASTIC LYMPHOMA KINASE INHIBITOR; ANTINEOPLASTIC AGENT; CRIZOTINIB; LDK 378; NVP TAE684; UNCLASSIFIED DRUG; VORINOSTAT;

ANTIPROLIFERATIVE ACTIVITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; DRUG APPROVAL; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; GERMANY; HUMAN; MAXIMUM TOLERATED DOSE; NEUROBLASTOMA; NONHUMAN; POINT MUTATION; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

CELL TRANSFORMATION, NEOPLASTIC; CHILD; CLINICAL TRIALS, PHASE I AS TOPIC; DNA MUTATIONAL ANALYSIS; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; GERMANY; HUMANS; NEOPLASM STAGING; NEUROBLASTOMA; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SULFONES;

EID: 84887839628     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0033-1357132     Document Type: Review

References (57)

1. Berry T., Luther W., Bhatnagar N. et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell: 2012; 22 117 130
2. Bochennek K., Esser R., Lehrnbecher T. et al. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma. Klinische Padiatrie: 2012; 224 139 142
3. Bresler S. C., Wood A. C., Haglund E. A. et al. Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Science translational medicine: 2011; 3 108ra114
4. Butrynski J. E., D'Adamo D. R., Hornick J. L. et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med: 2010; 363 1727 1733
5. Chen J., Jiang C., Wang S. LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor. Journal of medicinal chemistry: 2013; 10.1021/jm401005u
6. Chen Y., Takita J., Choi Y. L. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature: 2008; 455 971 974
7. Cheung N. K., Dyer M. A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature reviews Cancer: 2013; 13 397 411
8. Cheung N. K., Zhang J., Lu C. et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA: 2012; 307 1062 1071
9. Corbacioglu S. Early phase clinical trials in pediatric hematology and oncology. Klinische Padiatrie: 2012; 224 197 200
10. De Brouwer S., De Preter K., Kumps C. et al. Meta-analysis of neuro-blastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clinical cancer research: an official journal of the American Association for Cancer Research: 2010; 16 4353 4362
11. Dienstmann R., Rodon J., Barretina J. et al. Genomic medicine frontier in human solid tumors: prospects and challenges. Journal of clinical oncology: official journal of the American Society of Clinical Oncology: 2013; 31 1874 1884
12. Duijkers F. A., Gaal J., Meijerink J. P. et al. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels. Cellular oncology: 2011; 34 409 417
13. Duijkers F. A., Gaal J., Meijerink J. P. et al. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome. The American journal of pathology: 2012; 180 1223 1231
14. Eggert A. Update: personalized diagnostics and therapies for pediatric cancer patients. Klinische Padiatrie: 2013; 225 107 109
15. Galkin A. V., Melnick J. S., Kim S. et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA: 2007; 104 270 275 (Pubitemid 46068021)
16. George R. E., Attiyeh E. F., Li S. et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One: 2007; 2 e255
17. George R. E., Sanda T., Hanna M. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature: 2008; 455 975 978
18. Gobel U., Korholz D., Bernig T. et al. Treatment of children and adolecents with cancer after the application of the guide lines for good clinical practice in 2004 and the evaluation of new measurements. Klinische Padiatrie: 2012; 224 335 338
19. Grunewald T. G., Greulich N., Kontny U. et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klinische Padiatrie: 2012; 224 124 131
20. Heukamp L. C., Thor T., Schramm A. et al. Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Science translational medicine: 2012; 4 141ra191
21. Janoueix-Lerosey I., Lequin D., Brugieres L. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature: 2008; 455 967 970
22. Janoueix-Lerosey I., Schleiermacher G., Michels E. et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol: 2009; 27 1026 1033
23. Kwak E. L., Bang Y. J., Camidge D. R. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med: 2010; 363 1693 1703
24. Lamant L., Pulford K., Bischof D. et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol: 2000; 156 1711 1721 (Pubitemid 30646709)
25. Marsilje T. H., Pei W., Chen B. et al. Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4- (piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials. Journal of medicinal chemistry: 2013; 10.1021/jm400402q
26. Martinsson T., Eriksson T., Abrahamsson J. et al. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res: 2011; 71 98 105
27. McDermott U., Iafrate A. J., Gray N. S. et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res: 2008; 68 3389 3395
28. Mestdagh P., Fredlund E., Pattyn F. et al. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene: 2010; 29 3583 3592
29. Mestdagh P., Fredlund E., Pattyn F. et al. MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene: 2010; 29 1394 1404
30. Molenaar J. J., Domingo-Fernandez R., Ebus M. E. et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nature genetics: 2012; 44 1199 1206
31. Molenaar J. J., Koster J., Zwijnenburg D. A. et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature: 2012; 483 589 593
32. Morris S. W., Kirstein M. N., Valentine M. B. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science: 1994; 263 1281 1284 (Pubitemid 24107549)
33. Mosse Y. P., Laudenslager M., Longo L. et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature: 2008; 455 930 935
34. Mosse Y. P., Lim M. S., Voss S. D. et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. The lancet oncology: 2013; 14 472 480
35. Murugan A. K., Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res: 2011; 71 4403 4411
36. Oberthuer A., Berthold F., Warnat P. et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol: 2006; 24 5070 5078 (Pubitemid 46631411)
37. Otto T., Horn S., Brockmann M. et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell: 2009; 15 67 78
38. Passoni L., Longo L., Collini P. et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer research: 2009; 69 7338 7346
39. Pugh T. J., Morozova O., Attiyeh E. F. et al. The genetic landscape of high-risk neuroblastoma. Nature genetics: 2013; 45 279 284
40. Puissant A., Frumm S. M., Alexe G. et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer discovery: 2013; 3 308 323
41. Reiff T., Huber L., Kramer M. et al. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development: 2011; 138 4699 4708
42. Sasaki T., Okuda K., Zheng W. et al. The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers. Cancer Res: 2010; 70 10038 10043
43. Sausen M., Leary R. J., Jones S. et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature genetics: 2013; 45 12 17
44. Schleiermacher G., Janoueix-Lerosey I., Ribeiro A. et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol: 2010; 28 3122 3130
45. Schulte J. H., Bachmann H. S., Brockmeyer B. et al. High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma. Clin Cancer Res: 2011; 17 5082 5092
46. Schulte J. H., Lindner S., Bohrer A. et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene: 2013; 32 1059 1065
47. Schulte J. H., Marschall T., Martin M. et al. Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. Nucleic Acids Res: 2010; 38 5919 5928
48. Schulte J. H., Schowe B., Mestdagh P. et al. Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer: 2010; 127 2374 2385
49. Schwab M., Alitalo K., Klempnauer K. H. et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature: 1983; 305 245 248 (Pubitemid 14227614)
50. Seeger R. C., Brodeur G. M., Sather H. et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med: 1985; 313 1111 1116 (Pubitemid 16216827)
51. Simon T., Berthold F., Borkhardt A. et al. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatric blood & cancer: 2011; 56 578 583
52. Soda M., Choi Y. L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature: 2007; 448 561 566 (Pubitemid 47206930)
53. Trochet D., Bourdeaut F., Janoueix-Lerosey I. et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet: 2004; 74 761 764 (Pubitemid 38420106)
54. van Gaal J. C., Flucke U. E., Roeffen M. H. et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. Journal of clinical oncology: official journal of the American Society of Clinical Oncology: 2012; 30 308 315
55. Witt O., Milde T., Deubzer H. E. et al. Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klinische Padiatrie: 2012; 224 398 403
56. Yu A. L., Gilman A. L., Ozkaynak M. F. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med: 2010; 363 1324 1334
57. Zhu S., Lee J. S., Guo F. et al. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell: 2012; 21 362 373